You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical trials in severe sepsis with drotrecogin alfa (activated)
|
|---|---|
| Published in |
Critical Care, December 2007
|
| DOI | 10.1186/cc6156 |
| Pubmed ID | |
| Authors |
Pierre-François Laterre |
| Abstract |
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Evaluation of Medical Products also recommended that DrotAA could be administered to patients with severe sepsis and multiple organ dysfunction when added to the best standard care. Following the initial publication of the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) findings, multiple subgroup analyses supported the need for additional studies to explore the various hypotheses raised by this study. This review discusses all large clinical trials exploring the efficacy and safety of DrotAA and proposes recommendations for the use of DrotAA in severe sepsis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 5% |
| Germany | 1 | 2% |
| Spain | 1 | 2% |
| Unknown | 53 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 17% |
| Researcher | 10 | 17% |
| Student > Postgraduate | 6 | 10% |
| Professor > Associate Professor | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 16 | 28% |
| Unknown | 6 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 71% |
| Agricultural and Biological Sciences | 6 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Computer Science | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 5 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2012.
All research outputs
#17,285,668
of 25,374,647 outputs
Outputs from Critical Care
#5,469
of 6,554 outputs
Outputs of similar age
#143,081
of 167,938 outputs
Outputs of similar age from Critical Care
#20
of 28 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,554 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,938 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.